Recent clinical studies of the immunomodulatory drug (IMiD®) lenalidomide

被引：50

作者：

Bartlett, JB ^{[1
]}

Tozer, A ^{[1
]}

Stirling, D ^{[1
]}

Zeldis, JB ^{[1
]}

机构：

[1] Celgene Corp, Summit, NJ 07901 USA

来源：

BRITISH JOURNAL OF CANCER | 2005年 / 93卷 / 06期

关键词：

lenalidomide; thalidomide; multiple myeloma; myelodysplastic syndromes; immunomodulatory; angiogenesis;

D O I：

10.1038/sj.bjc.6602774

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thalidomide is effective in the treatment of multiple myeloma. The immunomodulatory drug and thalidomide analogue lenalidomide is currently in late stage clinical development for MDS and multiple myeloma. This minireview highlights the course of initial and ongoing lenalidomide clinical development in oncology with reference to earlier thalidomide studies.

引用

页码：613 / 619

页数：7

共 37 条

[11] Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas [J].

Fine, HA ;

Wen, PY ;

Maher, EA ;

Viscosi, E ;

Batchelor, T ;

Lakhani, N ;

Figg, WD ;

Purow, BW ;

Borkowf, CB .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2299-2304

[12]

Furman RR, 2005, J CLIN ONCOL, V23, p595S

[13] Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications [J].

Gupta, D ;

Treon, SP ;

Shima, Y ;

Hideshima, T ;

Podar, K ;

Tai, YT ;

Lin, B ;

Lentzsch, S ;

Davies, FE ;

Chauhan, D ;

Schlossman, RL ;

Richardson, P ;

Ralph, P ;

Wu, L ;

Payvandi, F ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

LEUKEMIA, 2001, 15 (12) :1950-1961

[14] Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].

Haslett, PAJ ;

Corral, LG ;

Albert, M ;

Kaplan, G .

JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892

[15] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].

Hideshima, T ;

Chauhan, D ;

Shima, Y ;

Raje, N ;

Davies, FE ;

Tai, YT ;

Treon, SP ;

Lin, B ;

Schlossman, RL ;

Richardson, P ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2000, 96 (09) :2943-2950

[16] Doxil (D), vincristine (V), reduced frequency dexamethasone (D) and revlimid(R) (DVd-R) a phase I/II trial in advanced relapsed refractory multiple myeloma (Rmm) patients. [J].

Hussein, MA ;

Karam, MA ;

Brand, C ;

Pearce, GL ;

Reed, J ;

Bruening, K ;

Sartori, P ;

Srkalovic, G ;

Olesnyckyj, M ;

Knight, R ;

Balinski, K ;

Zeldis, J .

BLOOD, 2004, 104 (11) :63A-64A

[17] Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma [J].

Kumar, S ;

Gertz, MA ;

Dispenzieri, A ;

Lacy, MQ ;

Geyer, SM ;

Iturria, NL ;

Fonseca, R ;

Hayman, SR ;

Lust, JA ;

Kyle, RA ;

Greipp, PR ;

Witzig, TE ;

Rajkumar, SV .

MAYO CLINIC PROCEEDINGS, 2003, 78 (01) :34-39

[18]

Lentzsch S, 2002, CANCER RES, V62, P2300

[19] Efficacy of lenalidomide in myelodysplastic syndromes [J].

List, A ;

Kurtin, S ;

Roe, DJ ;

Buresh, A ;

Mahadevan, D ;

Fuchs, D ;

Rimsza, L ;

Heaton, R ;

Knight, R ;

Zeldis, JB .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :549-557

[20]

List AF, 2005, J CLIN ONCOL, V23, p2S

← 1 2 3 4 →